Valuation: Lakefront Biotherapeutics NV

Market Cap 1.61B 1.84B 1.5B 1.38B 2.59B 177B 2.63B 17.83B 6.97B 87.03B 6.9B 6.75B 301B P/E 2026 *
-11.5x
P/E 2027 * -8.68x
Enterprise Value -369M -420M -343M -315M -591M -40.44B -600M -4.07B -1.59B -19.88B -1.58B -1.54B -68.74B EV / Sales 2026 *
-25.9x
EV / Sales 2027 * -8.22x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.13%
1 week-5.70%
Current month-6.56%
1 month-3.39%
3 months-0.89%
6 months-16.44%
Current year-12.50%
1 week 24.5
Extreme 24.5
26.46
1 month 24.5
Extreme 24.5
27.12
Current year 22.62
Extreme 22.62
30.72
1 year 22.62
Extreme 22.62
32.74
3 years 20
Extreme 20
40.26
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Chairman

1,559 0.0024%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Buy

Director

137 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-5.70%-13.79%-36.38% 1.86B
+1.07%-4.73%-3.96%+11.63% 46.35B
+0.25%+5.61%+404.21%+606.87% 40.13B
-0.27%+2.67%+10.54%+65.01% 36.33B
+0.35%-1.16%+7.11%-8.85% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.47%-2.29% - - 16.66B
-0.73%+11.80%+37.49%+145.18% 16.91B
+0.42%-4.46%+4.80%+8.67% 13.05B
-2.68%-2.49%-1.27%-32.60% 13.05B
Average +0.09%+0.45%+49.87%+88.27% 24.57B
Weighted average by Cap. +0.45%+0.73%+76.05%+130.79%

Financials

2026 *2027 *
Net sales 14.24M 16.21M 13.24M 12.15M 22.83M 1.56B 23.19M 157M 61.44M 768M 60.87M 59.55M 2.65B 46.09M 52.47M 42.86M 39.33M 73.9M 5.05B 75.04M 509M 199M 2.48B 197M 193M 8.59B
Net income -811M -923M -754M -692M -1.3B -88.89B -1.32B -8.95B -3.5B -43.7B -3.47B -3.39B -151B -238M -271M -221M -203M -381M -26.07B -387M -2.63B -1.03B -12.82B -1.02B -994M -44.32B
Net Debt -1.98B -2.26B -1.84B -1.69B -3.18B -217B -3.23B -21.9B -8.56B -107B -8.48B -8.29B -370B -1.99B -2.27B -1.85B -1.7B -3.2B -219B -3.25B -22.02B -8.6B -107B -8.52B -8.34B -372B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-07-24 €24.50 -1.13% 65,584
26-07-23 €24.78 -3.35% 108,761
26-07-22 €25.64 0.00% 49,642
26-07-21 €25.64 -0.23% 62,455
26-07-20 €25.70 -1.15% 72,797
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
24.50EUR
Average target price
30.28EUR
Spread / Average Target
+23.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock